NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
Clinical Trials
83 trialsNCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT05262335 2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2 Unknown
NCT04308837 2023-11-14
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
Icahn School of Medicine at Mount Sinai
Phase 2 Unknown
NCT05603065 2023-06-29
TINES
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Unknown
NCT02560298 2023-06-22
InterAACT
Eastern Cooperative Oncology Group
Phase 2 Unknown
NCT05751265 2023-06-22
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03094884 2023-05-23
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
Fox Chase Cancer Center
Phase 1 Unknown
NCT05853172 2023-05-10
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05541146 2023-03-23
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05580887 2022-10-14
Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients
Moscow Clinical Scientific Center
Unknown
NCT05522894 2022-08-31
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
ChineseAMS
Phase 2 Unknown
NCT05476380 2022-07-27
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT05394415 2022-05-27
LATE
Jiangsu Cancer Institute & Hospital
Phase 1/2 Unknown
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04808466 2022-02-21
WUHIPEC01
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT02970539 2022-02-16
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
Athenex, Inc.
Phase 1 Unknown
NCT05228743 2022-02-08
Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT05111444 2021-11-08
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Fudan University
Phase 2 Unknown
NCT04426955 2021-09-16
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05044728 2021-09-16
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT02934464 2021-09-13
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3 Unknown
NCT04063683 2021-08-24
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Henan Cancer Hospital
Phase 2 Unknown
NCT05013697 2021-08-19
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
Henan Cancer Hospital
Phase 2 Unknown
NCT04943653 2021-07-06
IPXELOX
Seoul St. Mary's Hospital
Phase 1/2 Unknown
NCT04915807 2021-06-07
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Hallym University Medical Center
Unknown
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT03791905 2021-03-23
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT02526953 2021-02-09
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
Blokhin's Russian Cancer Research Center
Phase 3 Unknown
NCT03989310 2020-12-23
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04555304 2020-09-18
Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
Chengdu Kanghong Biotech Co., Ltd.
Phase 2 Unknown
NCT04443036 2020-06-23
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
China Medical University, China
Phase NA Unknown
NCT04435652 2020-06-17
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
NCT02279134 2020-04-03
Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma
ChineseAMS
Phase 2/3 Unknown
NCT04286711 2020-02-27
Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
China Medical University, China
Phase 1/2 Unknown
NCT04053205 2019-08-12
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT02858206 2019-07-26
Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
ChineseAMS
Phase 2 Unknown
NCT04004234 2019-07-09
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03263741 2019-07-08
Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT04001569 2019-06-28
AZD8186 and Paclitaxel in Advanced Gastric Cancer
Seoul National University Bundang Hospital
Phase 1/2 Unknown
NCT03990103 2019-06-19
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
China Medical University, China
Phase 2 Unknown
NCT03966118 2019-06-03
AIO-STO-0218
Charite University, Berlin, Germany
Phase 2 Unknown
NCT03929094 2019-04-26
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT03286244 2019-02-21
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
AnewPharma
Phase 1 Unknown
NCT03308552 2019-01-02
Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
ChineseAMS
Phase 3 Unknown
NCT03328234 2019-01-02
Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03
ChineseAMS
Phase 3 Unknown